beclabuvir

Beclabuvir (BMS-791325) is an orally active, non-nucleoside inhibitor of the Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Developed by Bristol Myers Squibb, it is a small molecule direct-acting antiviral (DAA) belonging to the indolobenzazepine class. Beclabuvir works by binding to the Thumb 1 allosteric site of the NS5B polymerase, which is essential for viral genome replication. It was primarily developed for use in combination therapy to prevent the emergence of drug resistance. In clinical practice, it was evaluated as part of a triple-combination regimen alongside the NS5A inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir. This combination was approved in Japan for the treatment of patients with genotype 1 chronic HCV infection, although Bristol Myers Squibb later discontinued its broader HCV development program in other regions.

Brand names

Ximency

Other names

beclabuvirum